Therefore, examining SSX family gene expressions (i.e., cancer biomarkers) in a large number of patients with CC should provide insights that will aid in the early diagnosis of malignancy and, thus, increase the likelihood of successful therapy. This evidence concerns the gene SSX2B and cancer.